In8bio presents preclinical data on nsCAR platform

IN8bio announced the ability of its novel non-signaling gamma-delta CAR-T platform, nsCAR, to selectively target leukemic cells while preserving healthy B cells. The findings were presented by Dr. Lawrence Lamb, IN8bio’s Chief Scientific Officer, during a Plenary session titled "Leveraging the Nexus of the Immune System with Gamma-Delta CAR-T Cells" at the 6th CAR-TCR Summit Europe on February 23rd. "This powerful approach could be used in indications such as acute myeloid leukemia and solid tumor cancers where on-target, off-tumor expression would result in toxicities with significant risks to patients," said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. "While CD19 was a preclinical proof-of-concept, we look forward to advancing the nsCAR platform into solid tumor indications as well as promising targets for AML, such as CD33."